ADTX Overview

Aditxt, Inc. is a social innovation platform dedicated to accelerating promising health innovations. It develops and commercializes technologies with a focus on monitoring and modulating the immune system. Its portfolio includes Adimune, Inc., developing a new class of therapeutics designed to retrain the immune system to address organ rejection, autoimmunity, and allergies; Adivir, Inc., focused on identifying, developing, and commercializing new ways to treat infectious diseases, and Pearsanta, Inc., offering personalized lab testing, backed by CLIA-certified and CAP-accredited monitoring center. Adimune, Inc's immune modulation product candidate, ADI-100, is based on the Apoptotic DNA Immunotherapy platform technology, utilizes a novel approach that mimics the way bodies naturally induce tolerance to own tissues. It also offers electroencephalography (EEG) brain monitoring technologies and devices, including NeuroCap and NeuroEEG for telehealth and tele-neurology applications.

Wall Street analysts forecast ADTX stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for ADTX is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Aditxt Inc revenue for the last quarter amounts to 748.00 USD, decreased -89.09

Aditxt Inc. EPS for the last quarter amounts to -4390.25 USD, decreased -99.98

Aditxt Inc (ADTX) has 26 emplpoyees as of March 31 2026.

Today ADTX has the market capitalization of 408.64K USD.